Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.

Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S; and the VAST-D Investigators, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB 3rd, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT.

JAMA. 2017 Jul 11;318(2):132-145. doi: 10.1001/jama.2017.8036.

2.
3.

A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.

Schmid M, Sen M, Rosenbach MD, Carrera CJ, Friedman H, Carson DA.

Oncogene. 2000 Nov 23;19(50):5747-54.

4.

Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA, Leoni LM.

Blood. 2000 Nov 15;96(10):3537-43.

5.

Rational design, synthesis and structure-activity relationships of antitumor (E)-2-benzylidene-1-tetralones and (E)-2-benzylidene-1-indanones.

Shih H, Deng L, Carrera CJ, Adachi S, Cottam HB, Carson DA.

Bioorg Med Chem Lett. 2000 Mar 6;10(5):487-90.

PMID:
10743954
6.

Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells.

Leoni LM, Hamel E, Genini D, Shih H, Carrera CJ, Cottam HB, Carson DA.

J Natl Cancer Inst. 2000 Feb 2;92(3):217-24.

PMID:
10655438
7.

Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway.

Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, Carson DA, Leoni LM.

J Biol Chem. 2000 Jan 7;275(1):29-34.

8.

Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.

Batova A, Diccianni MB, Omura-Minamisawa M, Yu J, Carrera CJ, Bridgeman LJ, Kung FH, Pullen J, Amylon MD, Yu AL.

Cancer Res. 1999 Apr 1;59(7):1492-7.

9.
10.

Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c.

Leoni LM, Chao Q, Cottam HB, Genini D, Rosenbach M, Carrera CJ, Budihardjo I, Wang X, Carson DA.

Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9567-71.

11.

The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia.

Hori Y, Hori H, Yamada Y, Carrera CJ, Tomonaga M, Kamihira S, Carson DA, Nobori T.

Int J Cancer. 1998 Jan 5;75(1):51-6.

13.

Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.

Hori H, Tran P, Carrera CJ, Hori Y, Rosenbach MD, Carson DA, Nobori T.

Cancer Res. 1996 Dec 15;56(24):5653-8.

14.

Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report.

Eibschutz B, Baird SM, Weisman MH, Amox DG, Spellman M, Piacquadio D, Carrera CJ, Carson DA.

Arthritis Rheum. 1995 Nov;38(11):1604-9.

PMID:
7488281
15.

Purine metabolism of lymphocytes. Targets for chemotherapy drug development.

Carrera CJ, Saven A, Piro LD.

Hematol Oncol Clin North Am. 1994 Apr;8(2):357-81. Review.

PMID:
8040145
16.

Marrow suppression produced by repeated doses of cladribine.

Beutler E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ.

Acta Haematol. 1994;91(1):10-5.

PMID:
8171930
17.

2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.

Saven A, Kawasaki H, Carrera CJ, Waltz T, Copeland B, Zyroff J, Kosty M, Carson DA, Beutler E, Piro LD.

J Clin Oncol. 1993 Apr;11(4):671-8.

PMID:
8097527
18.

Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.

Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA.

Blood. 1993 Feb 1;81(3):597-601.

19.

Hairy cell leukemia: new understanding of biology and treatment.

Saven A, Piro LD, Carrera CJ, Carson DA, Beutler E.

Cancer Treat Res. 1993;64:15-34. Review. No abstract available.

PMID:
7680875
20.

Quantitative immunoassay of human deoxycytidine kinase in malignant cells.

Kawasaki H, Carrera CJ, Carson DA.

Anal Biochem. 1992 Nov 15;207(1):193-6.

PMID:
1489095
21.

2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.

Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD.

Blood. 1992 Aug 1;80(3):587-92.

22.

Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine.

Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, Cottam HB.

Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2970-4.

23.

2-Chlorodeoxyadenosine treatment of low-grade lymphomas.

Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, Piro LD.

J Clin Oncol. 1992 Mar;10(3):371-7.

PMID:
1346801
24.

Dependence of cell survival on DNA repair in human mononuclear phagocytes.

Terai C, Wasson DB, Carrera CJ, Carson DA.

J Immunol. 1991 Dec 15;147(12):4302-6.

PMID:
1753100
25.

Deoxyadenosine-resistant human T lymphoblasts with elevated 5'-nucleotidase activity.

Carson DA, Carrera CJ, Wasson DB, Iizasa T.

Biochim Biophys Acta. 1991 Jan 10;1091(1):22-8.

PMID:
1995064
26.

2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia.

Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD.

Leuk Lymphoma. 1991;5 Suppl 1:133-8. doi: 10.3109/10428199109103394.

PMID:
27463495
27.

2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside.

Beutler E, Piro LD, Saven A, Kay AC, McMillan R, Longmire R, Carrera CJ, Morin P, Carson DA.

Leuk Lymphoma. 1991;5(1):1-8. doi: 10.3109/10428199109068099.

PMID:
27463204
28.

2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes.

Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA.

Adv Exp Med Biol. 1991;309A:15-8. No abstract available.

PMID:
1686349
29.

Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.

Carrera CJ, Terai C, Lotz M, Curd JG, Piro LD, Beutler E, Carson DA.

J Clin Invest. 1990 Nov;86(5):1480-8.

30.

Immunodeficiency secondary to adenosine deaminase deficiency and purine nucleoside phosphorylation deficiency.

Carson DA, Carrera CJ.

Semin Hematol. 1990 Jul;27(3):260-9. Review. No abstract available.

PMID:
2115692
31.

Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.

Piro LD, Carrera CJ, Carson DA, Beutler E.

N Engl J Med. 1990 Apr 19;322(16):1117-21.

32.

2-halo-2',3'-dideoxyadenosines: metabolically stable dideoxynucleosides with activity against the human immunodeficiency virus (HIV).

Carson DA, Haertle T, Carrera CJ, Willis EH, Wasson DB, Richman DD.

Adv Exp Med Biol. 1989;253B:395-8. No abstract available.

PMID:
2610127
33.

Activity of 2-chloro-2'-deoxyadenosine in chronic lymphocytic leukemia, hairy cell leukemia, and autoimmune hemolytic anemia.

Carson DA, Piro LD, Wasson DB, Carrera CJ, Beutler E.

Adv Exp Med Biol. 1989;253A:427-31. Review. No abstract available.

PMID:
2576181
34.

Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo.

Carrera CJ, Yamanaka H, Piro LD, Lotz M, Carson DA.

Adv Exp Med Biol. 1989;253B:219-25.

PMID:
2575348
35.

2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.

Piro LD, Carrera CJ, Beutler E, Carson DA.

Blood. 1988 Sep;72(3):1069-73.

36.

Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives.

Haertle T, Carrera CJ, Wasson DB, Sowers LC, Richman DD, Carson DA.

J Biol Chem. 1988 Apr 25;263(12):5870-5.

37.

Methylthioadenosine (MeSAdo) phosphorylase deficiency in malignancy.

Carson DA, Nobori T, Kajander EO, Carrera CJ, Kubota M, Yamanaka H.

Adv Exp Med Biol. 1988;250:179-85. Review. No abstract available.

PMID:
3151225
38.

Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes.

Carson DA, Carrera CJ, Wasson DB, Yamanaka H.

Adv Enzyme Regul. 1988;27:395-404.

PMID:
2907967
39.
40.

DNA strand breaks, NAD metabolism, and programmed cell death.

Carson DA, Seto S, Wasson DB, Carrera CJ.

Exp Cell Res. 1986 Jun;164(2):273-81.

PMID:
2940104
41.

Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes.

Seto S, Carrera CJ, Wasson DB, Carson DA.

J Immunol. 1986 Apr 15;136(8):2839-43.

PMID:
2870121
42.

5'-deoxy-5'-methylthioadenosine phosphorylase deficiency in leukemia: genetics and biochemical aspects.

Carrera CJ, Willis EH, Chilcote RR, Kubota M, Carson DA.

Adv Exp Med Biol. 1986;195 Pt B:643-50. No abstract available.

PMID:
3094332
43.

Genetic analysis of deoxyadenosine toxicity in dividing human lymphoblasts.

Carson DA, Carrera CJ, Kubota M, Wasson DB, Iizasa T.

Adv Exp Med Biol. 1986;195 Pt B:207-11. No abstract available.

PMID:
3020905
44.

Biochemical basis for deoxyadenosine and 2-chlorodeoxyadenosine toxicity to resting human lymphocytes.

Seto S, Carrera CJ, Wasson DB, Carson DA.

Adv Exp Med Biol. 1986;195 Pt B:577-82. No abstract available.

PMID:
2876594
45.

Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA.

J Clin Invest. 1985 Feb;75(2):377-83.

46.

Metabolic basis for immune dysfunction in adenosine deaminase deficiency.

Carson DA, Iizasa T, Seto S, Carrera CJ, Kubota M, Willis EH, Wasson DB, Kajander O.

Ann N Y Acad Sci. 1985;451:34-41. No abstract available.

PMID:
3878120
47.

Deoxynucleoside overproduction in deoxyadenosine-resistant, adenosine deaminase-deficient human histiocytic lymphoma cells.

Kubota M, Carrera CJ, Wasson DB, Carson DA.

Biochim Biophys Acta. 1984 May 22;804(1):37-43.

PMID:
6372866
48.
49.

Uptake and metabolism of daunorubicin by human leukemia cells.

DeGregorio MW, Carrera CJ, Klock JC, Wilbur JR.

Cancer Chemother Pharmacol. 1982 Dec;10(1):29-32.

PMID:
6961971
50.

Cellular and plasma kinetics of daunorubicin given by two methods of administration in a patient with acute leukemia.

DeGregorio MW, Carrera CJ, Klock JC, Pegelow CH, Wilbur JR.

Cancer Treat Rep. 1982 Dec;66(12):2085-8.

PMID:
6958366

Supplemental Content

Loading ...
Support Center